Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 2/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.36 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.35 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3569096 | 0.86 | PTGES (0.43) | PTGESPDE4AFFAR4ALDH1A1TSHR | |
| SCHEMBL27677014 | 0.76 | PDE4A (0.38) | PDE4AFFAR4ALDH1A1TAOK1PDE4B | |
| SCHEMBL3578441 | 0.75 | PTGES (0.47) | PTGESKCNH2 | |
| SCHEMBL3578255 | 0.75 | PTGES (0.69) | PTGESPDE4AALDH1A1TSHRHRH3 | |
| SCHEMBL3579044 | 0.75 | MAPT (0.39) | PTGESALDH1A1TSHR | |
| SCHEMBL4697234 | 0.73 | MAP4K4 (0.53) | PTGESPDE4AALDH1A1TSHRKCNH2 | |
| SCHEMBL3576474 | 0.71 | PTGES (0.71) | PTGESALDH1A1TSHRHRH3KCNH2 | |
| SCHEMBL4914710 | 0.70 | ALDH1A1 (0.38) | PTGESALDH1A1TSHRHRH3KCNH2 | |
| SCHEMBL4099631 | 0.69 | MAP4K4 (0.39) | PTGESFFAR4HRH3KCNH2 | |
| SCHEMBL4923166 | 0.68 | EPHX2 (0.39) | PTGESALDH1A1TSHRHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705023-B2 | Indoles useful in the treatment of inflammation | BIOLIPOX AB (SE) | 2010-04-27 | — | — | US | disclosed |
| EP-1778632-B1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2008-08-20 | — | — | EP | disclosed |
| US-20070287715-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287715-A1 | Indoles Useful in the Treatment of Inflammation | PTGS1, IDO1, PTGES | PTGES 3/4885PDE4A 1851/4885FFAR4 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.